Litcius/Paper detail

Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and <i>Enterobacterales</i>

Dina Zheng, Phillip J. Bergen, Cornelia B. Landersdorfer, Elizabeth B. Hirsch

2021Antimicrobial Agents and Chemotherapy29 citationsDOIOpen Access PDF

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa presents a serious threat to public health due to its widespread resistance to numerous antibiotics. P. aeruginosa commonly causes nosocomial infections including urinary tract infections (UTI) which have become increasingly difficult to treat. The lack of effective therapeutic agents has renewed interest in fosfomycin, an old drug discovered in the 1960s and approved prior to the rigorous standards now required for drug approval.

Topics & Concepts

FosfomycinPseudomonas aeruginosaMicrobiologyDrug resistanceAntibioticsBiologyResistomeEscherichia coliAntibiotic resistanceEffluxPeptidoglycanBiofilmAntibacterial agentCross-resistanceBacteriarpoSMultiple drug resistanceBacterial geneticsUrinary Tract Infections ManagementAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and Efficacy
Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and <i>Enterobacterales</i> | Litcius